Conventional Chemotherapy Nephrotoxicity.

Conventional chemotherapies remain the mainstay of treatment for many malignancies. Kidney complications of these therapies are not infrequent and may have serious implications for future kidney function, cancer treatment options, eligibility for clinical trials, and overall survival. Kidney adverse effects may include acute kidney injury (via tubular injury, tubulointerstitial nephritis, glomerular disease and thrombotic microangiopathy), long-term kidney function loss and CKD, and electrolyte disturbances. In this review, we summarize the kidney complications of conventional forms of chemotherapy and, where possible, provide estimates of incidence, and identify risk factors and strategies for kidney risk mitigation. In addition, we provide recommendations regarding kidney dose modifications, recognizing that these adjustments may be limited by available supporting pharmacokinetic and clinical outcomes data. We discuss management strategies for kidney adverse effects associated with these therapies with drug-specific recommendations. We focus on frequently used anticancer agents with established kidney complications, including platinum-based chemotherapies (cisplatin, carboplatin, oxaliplatin), cyclophosphamide, gemcitabine, ifosfamide, methotrexate and pemetrexed, among others.

• Publication year

  2021

• Venue

  Advances in Chronic Kidney Disease

• Publication date

  2021-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.ackd.2021.08.001PMID 35190107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer therapy-induced hyponatremia: A case-illustrated review

  2021cited by this paper
• Defining cisplatin eligibility in patients with muscle-invasive bladder cancer

  2021cited by this paper
• Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations

  2021cited by this paper
• Cumulative pemetrexed dose increases the risk of nephrotoxicity.

  2020cited by this paper
• New Treatment Options for Advanced Biliary Tract Cancer

  2020cited by this paper
• Carboplatin and hypomagnesemia: Is it really a problem?

  2020cited by this paper
• Canagliflozin reduces cisplatin uptake and activates Akt to protect against cisplatin-induced nephrotoxicity.

  2020cited by this paper
• Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.

  2019cited by this paper
• Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis

  2019cited by this paper
• Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity

  2019cited by this paper
• A case of biopsy-proven oxaliplatin-induced acute tubulointerstitial nephritis with thrombocytopenia and anemia

  2019cited by this paper
• Ifosfamide nephrotoxicity in adult patients

  2019cited by this paper
• Acute Kidney Injury in Patients With Cancer.

  2018cited by this paper
• Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort

  2018cited by this paper
• Impact of aging on the risk of platinum-related renal toxicity: A systematic review and meta-analysis.

  2018cited by this paper
• The use of eculizumab in gemcitabine induced thrombotic microangiopathy

  2018cited by this paper
• Acquired Gitelman Syndrome Secondary to Bendamustine Use.

  2018cited by this paper
• Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study

  2018cited by this paper
• Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function

  2018cited by this paper
• Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead.

  2018cited by this paper
• A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.

  2017cited by this paper
• Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study

  2017cited by this paper
• Oxaliplatin-induced acute tubulointerstitial nephritis: Two case reports
.

  2017cited by this paper
• Bendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis.

  2017cited by this paper
• Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.

  2017cited by this paper
• Thrombotic Microangiopathy Following Chemotherapy with S-1 and Cisplatin in a Patient with Gastric Cancer: A Case Report.

  2017cited by this paper
• Acute Kidney Injury in Patients with Cancer.

  2017cited by this paper
• Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling.

  2017cited by this paper
• Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity

  2016cited by this paper
• Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

  2016cited by this paper
• Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.

  2016cited by this paper
• Pemetrexed-Induced Nephrogenic Diabetes Insipidus.

  2016cited by this paper
• Preventing and Managing Toxicities of High-Dose Methotrexate

  2016cited by this paper
• Long-Term Renal Outcomes after Cisplatin Treatment.

  2016cited by this paper
• Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin.

  2015cited by this paper
• Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage

  2015cited by this paper
• Thrombotic microangiopathy, cancer, and cancer drugs.

  2015cited by this paper
• Acute Methotrexate-Induced Crystal Nephropathy.

  2015cited by this paper
• A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN).

  2015cited by this paper
• Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer.

  2014cited by this paper
• High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis

  2014cited by this paper
• Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis

  2014cited by this paper
• Pemetrexed-induced acute kidney injury leading to chronic kidney disease.

  2014cited by this paper
• Cisplatin in cancer therapy: molecular mechanisms of action.

  2014cited by this paper
• Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.

  2014cited by this paper
• Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy.

  2014cited by this paper
• Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review.

  2014cited by this paper
• Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study

  2014cited by this paper
• Severe acute tubular necrosis observed subsequent to oxaliplatin administration

  2013cited by this paper
• Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

  2013cited by this paper
• Effect of ketoprofen and indomethacin on methotrexate pharmacokinetics in mice plasma and tumor tissues

  2013cited by this paper
• Onco-nephrology: AKI in the cancer patient.

  2012cited by this paper
• Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats.

  2012cited by this paper
• Carboplatin

  2012cited by this paper
• Onco-nephrology: renal toxicities of chemotherapeutic agents.

  2012cited by this paper
• Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?

  2012cited by this paper
• A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

  2012cited by this paper
• Long term renal toxicity of ifosfamide in adult patients--5 year data.

  2012cited by this paper
• Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria.

  2011cited by this paper
• Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).

  2011cited by this paper
• Methotrexate in the urine.

  2011cited by this paper
• Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study.

  2011cited by this paper
• Doxorubicin pathways: pharmacodynamics and adverse effects

  2011cited by this paper
• Kidney tubular toxicity of maintenance pemetrexed therapy.

  2011cited by this paper
• Cisplatin-Induced Renal Salt Wasting Syndrome

  2010cited by this paper
• Mechanisms of Cisplatin Nephrotoxicity

  2010cited by this paper
• Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report

  2010cited by this paper
• Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity.

  2010cited by this paper
• Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma

  2010cited by this paper
• Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.

  2010cited by this paper
• Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.

  2010cited by this paper
• Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.

  2010cited by this paper
• An association between transient hypokalemia and severe acute oxaliplatin-related toxicity predominantly in women

  2010cited by this paper
• Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed

  2010cited by this paper
• Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats

  2009cited by this paper
• Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.

  2009cited by this paper
• Doxorubicin: the good, the bad and the ugly effect.

  2009cited by this paper
• Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.

  2009cited by this paper
• Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin‐Induced Nephrotoxicity

  2009cited by this paper
• American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

  2009cited by this paper
• Chemotherapy-associated renal dysfunction

  2009cited by this paper
• Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats

  2009cited by this paper
• Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.

  2008cited by this paper
• Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin

  2008cited by this paper
• Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.

  2007cited by this paper
• Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report.

  2007cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• The development of platinum compounds and their possible combination.

  2006cited by this paper
• Rosiglitazone ameliorates cisplatin-induced renal injury in mice.

  2006cited by this paper
• Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer

  2006cited by this paper
• Understanding and managing methotrexate nephrotoxicity.

  2006cited by this paper
• A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination

  2005cited by this paper
• Renal toxicity of oxaliplatin.

  2005cited by this paper
• Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution

  2005cited by this paper
• Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm

  2005cited by this paper
• Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2.

  2005cited by this paper
• Cellular processing of platinum anticancer drugs

  2005cited by this paper
• Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.

  2005cited by this paper
• Peroxynitrite may be involved in bladder damage caused by cyclophosphamide in rats.

  2005cited by this paper
• Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II

  2004cited by this paper

• Drug-related proteinuria: a vigilance analysis based on the FAERS database.

  2026cites this paper
• Does perioperative chemotherapy affect renal function after radical nephroureterectomy for upper tract urothelial carcinoma?

  2026cites this paper
• Carvedilol attenuates doxorubicin-evoked renal toxicity in rats: The role of PI3K/AKT/mTOR, Nrf2/HO-1 and Bax/Bcl2 signals.

  2026cites this paper
• Using Density Functional Theory (DFT) Calculations to Reinterpret the Biological Activity of Square Planar Pt (II), Au (III), and Cu (II) Complexes From Molecular Level

  2026cites this paper
• Onkonephrologie

  2026influential citation
• Acute kidney injury associated with cancer therapies: A focus on conventional chemotherapies and targeted treatments

  2026cites this paper
• Therapeutic Potential of Wogonin–Aloperine Co-Amorphous for Oral Squamous Cell Carcinoma

  2025cites this paper
• Development of a highly efficient DNA-based biosensor using a functionalized MoS₂/polypyrrole nanocomposite for mitomycin C determination.

  2025cites this paper
• Tailoring traditional Chinese medicine in cancer therapy

  2025cites this paper
• The Role of Mdivi-1 in Reducing Mitochondrial Fission via the NF-κB/JNK/SIRT3 Signaling Pathway in Acute Kidney Injury

  2025cites this paper
• Systemic delivery of sorafenib tosylate loaded LeciPlex®: A comparative assessment of nano assembly, biocompatibility, and In vivo drug disposition

  2025cites this paper
• An Adverse Outcome Pathway for DNA adduct formation leading to kidney failure.

  2025cites this paper
• Phase II Study of Short Hydration without Diuretics for Cisplatin-Based Chemotherapy.

  2025cites this paper
• Onco-nephrology in clinical practice: pharmacokinetics, monitoring, and treatment strategies for patients with cancer and impaired renal function

  2025cites this paper
• Identification of shared diagnostic biomarkers and potential co-morbidity mechanisms between primary Sjogren’s syndrome and chronic kidney disease

  2025cites this paper
• The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.

  2025cites this paper
• Hepatoprotective potential of solvent-derived artichoke leaf extracts against cyclophosphamideinduced liver injury in rat model.

  2025cites this paper
• Dosing of Anticancer Therapy in Patients with CKD

  2025cites this paper
• Renal Insufficiency After Colectomy for Colon Cancer.

  2025cites this paper
• Anticancer drug-induced nephrotoxicity: biopsy-proven patterns and outcomes across chemotherapy, targeted therapy, and immune checkpoint inhibitors

  2025cites this paper
• Perioperative approach to nephrotoxicity in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

  2025cites this paper
• Engineered chitosan nanoparticles: Harnessing bioresources for advanced multifunctional synergy in anticancer nanoplatforms.

  2025cites this paper
• Study the Effect of Type and Duration of Treatment on Some Hematological and Biochemical Variables of Lymphoma Patients in Al-Muthanna Province, Iraq

  2024cites this paper
• Synthesis, characterization, crystal structures and cytotoxic activity of Pt(II) complexes with N,N-donor ligands in tumor cell lines

  2024cites this paper
• Capecitabine-Related Thrombotic Microangiopathy

  2024cites this paper
• Identification Drug Targets for Oxaliplatin-Induced Cardiotoxicity without Affecting Cancer Treatment through Inter Variability Cross-Correlation Analysis (IVCCA)

  2024cites this paper
• Folate conjugated albumin as a targeted nanocarrier for the delivery of fisetin: in silico and in vitro biological studies

  2024cites this paper
• Qualitative chemical compounds analysis and in vitro estimation of antiproliferative, antidiabetic and anti-Alzheimer’s disease effects of Ononis natrix (L.) family Fabaceae

  2024cites this paper
• Reducing renal function assessment prior to platinum-based chemotherapy: a real-world evaluation

  2024cites this paper
• Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy

  2024influential citation
• The renoprotective potential of montelukast: a scoping review

  2024cites this paper
• Cancer drugs and acute kidney injury: new therapies and new challenges

  2024cites this paper
• Ifosfamide-induced acute kidney injury and confusional syndrome in a patient with diffuse large B-cell lymphoma.

  2024cites this paper
• Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials

  2024cites this paper
• Ozone Therapy in the Integrated Treatment of Female Dogs with Mammary Cancer: Oxidative Profile and Quality of Life

  2024cites this paper
• Platinum-based chemotherapy: trends in organic nanodelivery systems.

  2024cites this paper
• Injectable polypeptide-polysaccharide depot for preventing postoperative tumor recurrence by concurrent in situ chemotherapy and brachytherapy

  2024cites this paper
• Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding

  2024cites this paper
• A Case of Primary Ewing Sarcoma of the Kidney: Robotic-Assisted Nephron-Sparing Surgery, a Feasible Alternative in Treatment of Localized Disease

  2024cites this paper
• Patients’ knowledge about renal secondary effects of anti-tumoral drugs and renal protection measures

  2024cites this paper
• Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management

  2024cites this paper
• Onco-Nephrology: Kidney Disease in the Cancer Patient.

  2023cites this paper
• Unveiling drug induced nephrotoxicity using novel biomarkers and cutting-edge preventive strategies.

  2023cites this paper
• Ifosfamide-induced nephrotoxicity in oncological patients

  2023cites this paper
• Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review

  2023cites this paper
• Chemoradiotherapy treatment with gemcitabine improves renal function in locally advanced cervical cancer patients with renal dysfunction.

  2023cites this paper
• Nomogram based on pretreatment hepatic and renal function indicators for survival prediction of locally advanced esophageal squamous cell carcinoma with treatment of neoadjuvant chemoradiotherapy plus surgery

  2023cites this paper
• Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6

  2023cites this paper
• POTENTIAL AMELIORATIVE EFFECT OF PROPOLIS AGAINST THE DEVELOPMENTAL TOXICITY INDUCED BY OXALIPLATIN IN ALBINO RATS PRIOR AND DURING PREGNANCY

  2023cites this paper
• Early clinical indicators of acute kidney injury caused by administering high-dose methotrexate therapy to juvenile pigs

  2023cites this paper
• Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma

  2023cites this paper
• Replacement of Antiretroviral Therapy with HIV Broadly Neutralizing Antibodies to Maximize the Effectiveness of Chemotherapy in HIV Patients with Lung Cancer

  2023cites this paper
• Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes

  2022cites this paper
• Chronic Kidney Disease Prevalence in Patients with Colorectal Cancer Undergoing Surgery

  2022cites this paper
• 2-Methoxyestradiol TPGS Micelles Attenuate Cyclosporine A-Induced Nephrotoxicity in Rats through Inhibition of TGF-β1 and p-ERK1/2 Axis

  2022cites this paper
• Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies.

  2022cites this paper